CEO Martine Rothblatt Executes Strategic 10‑b5‑1 Trading Plan at United Therapeutics

Insider Activity Highlights a Strategic Trading Plan

On 13 October 2026, Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp., executed a transaction under the company’s 10 b5‑1 trading plan. The plan, adopted in November 2025, permits the conversion of options into shares according to a pre‑arranged schedule, thereby mitigating market‑timing risk. In the transaction that day, Rothblatt purchased 9,500 shares at $117.76 per share and sold a total of 6,390 shares at prices ranging from $542.76 to $550.59. The net effect of the trade is a modest increase in her holdings, bringing her post‑transaction ownership to 333,943 shares.

Implications for Investors

The simultaneous buying and selling activity reflects a disciplined, plan‑driven approach rather than opportunistic trading. For market participants, the key takeaway is that the CEO is not exploiting insider information to capitalize on short‑term price swings; instead, she is fulfilling a long‑term liquidity plan. The transaction size—less than 0.2 % of outstanding shares—minimises market impact and should not trigger significant volatility. However, the large number of shares sold in the same period may indicate a desire to diversify risk or prepare for future option exercises, which could influence short‑term liquidity dynamics.

Signals About the Company’s Future

United Therapeutics’ robust fundamentals—market capitalization of $23.6 billion, a year‑to‑date gain of 24.8 %, and a price‑to‑earnings ratio of 19.6—suggest a healthy growth trajectory. The CEO’s structured plan signals confidence in the company’s long‑term prospects while maintaining liquidity for potential future investments or personal needs. If the 10 b5‑1 plan continues, investors can expect periodic, predictable sales that provide an opportunity to benchmark the company’s share price against broader market movements without the risk of insider manipulation.

Rothblatt’s Trading Pattern – A Profile

Rothblatt’s trading history over the last few weeks shows a consistent pattern of exercising options in a staggered fashion and selling the resulting shares in multiple trades. Since the 10 b5‑1 plan went into effect, she has executed roughly 60–70 trades per month, selling shares at incremental price points from the low hundreds to the high five hundreds. Her buying activity remains limited to a few large purchases (e.g., 9,500 shares at $117.76), often paired with a subsequent sell of option‑derived shares. This disciplined cadence is typical of a “plan‑first, trade‑later” strategy used by senior executives to mitigate conflict‑of‑interest concerns and align personal liquidity needs with corporate performance.

Key Takeaways for Market Participants

For analysts and investors, monitoring the continuation of this plan can serve as a gauge of management’s confidence and liquidity strategy, while the company’s solid biotech fundamentals and steady share performance provide a compelling backdrop for ongoing investment evaluation.

Detailed Transaction Table

All figures are reported in U.S. dollars.